MicroPulse Transscleral Diode: An Effective Non-Surgical Treatment Alternate for Glaucoma

Aim: To determine the efficacy and safety of MicroPulse transscleral laser therapy (MP-TLT) in different types of glaucoma. Study design: Interventional case series. Duration and Settings of the study: This study was conducted from October 2022 to May 2023 at Bodla Eye Care, Multan, Pakistan. Methods: Patients with various types of glaucoma, such as open-angle glaucoma, closed-angle glaucoma, neovascular glaucoma, and pseudophakia glaucoma, with varying degrees of severity from mild to severe, were recruited. Pre- and post-treatment records included best-corrected visual acuity (BCVA), intraocular pressure (IOP), and number of glaucoma drugs taken. Records were kept on the number of therapy sessions, success rates, and postoperative complications. The follow-up records were recorded from October 2022 to June 2023. Results: Twenty eyes from 20 patients were included in the final analysis. Fourteen (70%) patients were males and their ages ranged from to 20-65 years in the study group. The average IOP reduction rate was 43 % at 12 weeks of follow, which was statistically significant (p<0.001). MP-TLT is partially effective in patients with closed-angle glaucoma. In 4 of 15 patients, posterior uveitis developed in 3rd week which resolved with the use of topical and systemic steroids in the 5th week. Conclusion: MicroPulse TLT is safe and effective for lowering IOP in a variety of glaucoma types with different severities. MicroPulse TLT had a lower complication rate.